GTS Securities LLC Reduces Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

GTS Securities LLC trimmed its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 54.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,329 shares of the pharmaceutical company's stock after selling 3,958 shares during the quarter. GTS Securities LLC's holdings in Vertex Pharmaceuticals were worth $1,341,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. ABC Arbitrage SA purchased a new position in Vertex Pharmaceuticals during the 4th quarter valued at $1,510,000. Highview Capital Management LLC DE raised its position in Vertex Pharmaceuticals by 1.8% during the 4th quarter. Highview Capital Management LLC DE now owns 5,771 shares of the pharmaceutical company's stock worth $2,324,000 after buying an additional 102 shares during the last quarter. Davidson Investment Advisors lifted its holdings in shares of Vertex Pharmaceuticals by 26.0% in the 4th quarter. Davidson Investment Advisors now owns 61,161 shares of the pharmaceutical company's stock valued at $24,630,000 after buying an additional 12,631 shares during the period. Jones Financial Companies Lllp grew its position in Vertex Pharmaceuticals by 75.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,468 shares of the pharmaceutical company's stock valued at $994,000 after buying an additional 1,062 shares during the period. Finally, Concord Wealth Partners raised its stake in shares of Vertex Pharmaceuticals by 32.6% during the 4th quarter. Concord Wealth Partners now owns 3,508 shares of the pharmaceutical company's stock worth $1,413,000 after buying an additional 862 shares during the period. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of the stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $475.34, for a total value of $251,930.20. Following the completion of the sale, the executive vice president now owns 58,539 shares in the company, valued at approximately $27,825,928.26. This represents a 0.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. This trade represents a 10.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,813 shares of company stock worth $1,889,514. 0.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on VRTX. Erste Group Bank cut Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. The Goldman Sachs Group reaffirmed a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Leerink Partners restated a "market perform" rating and set a $503.00 target price (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald reiterated an "overweight" rating and set a $535.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Fourteen analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $515.04.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded down $0.90 during mid-day trading on Wednesday, reaching $445.10. The stock had a trading volume of 1,207,666 shares, compared to its average volume of 1,418,257. The company has a market cap of $114.30 billion, a P/E ratio of -202.32, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The business's 50 day moving average price is $473.44 and its 200 day moving average price is $461.96. The company has a current ratio of 2.69, a quick ratio of 2.35 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Vertex Pharmaceuticals's revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $4.76 earnings per share. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.